Overview


According to FutureWise analysis, the market for Bacterial Sialadenitis is expected to grow with a CAGR of 5.60% over the forecast period 2023-2031, and reach a market value of US$ 2.93 Billion by 2031.

Bacterial sialadenitis is a medical condition characterized by the inflammation of one or more salivary glands due to a bacterial infection. These glands, known as salivary glands, are responsible for producing saliva, which aids in digestion and maintains oral health. Bacterial sialadenitis most commonly affects the major salivary glands, particularly the parotid gland in front of the ear and the submandibular gland beneath the jaw. The condition arises when bacteria, often originating from the mouth, enter the ducts that carry saliva from the glands to the mouth. This can occur due to dehydration, reduced saliva flow, or the presence of stones or strictures within the ducts, which can impede the normal flow of saliva and create an environment conducive to bacterial growth.

The hallmark symptoms of bacterial sialadenitis include localized pain and swelling in the affected gland, particularly during or shortly after meals when saliva production is stimulated. Additionally, individuals may experience dry mouth, fever, and a foul taste. If left untreated, the infection can progress, potentially leading to an abscess, a pocket of pus within the gland. Treatment often consists of a combination of antibiotics to target the underlying bacterial infection and measures to stimulate saliva flow, such as increased hydration, sour candies, or massage of the affected gland. In cases where an abscess has formed, drainage may be necessary.

FutureWise Market Research has published a report that provides an insightful analysis of Bacterial Sialadenitis Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Bacterial Sialadenitis Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Sanofi S.A.
  • Johnson & Johnson
  • Abbott Laboratories
  • Eli Lilly and Company
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Roche Holding AG
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Allergan plc

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Bacterial Sialadenitis Market:

  • In June 2021, Alfasigma revealed that it had secured European licensing approval for bentracimab, a groundbreaking human monoclonal antibody fragment obtained from PhaseBio. Extensive clinical trials have demonstrated bentracimab's effectiveness in reversing the antiplatelet effects of Brilinta / Brilique. 

The rising prevalence of bacterial sialadenitis, often attributed to dehydration, reduced saliva flow, and oral hygiene issues, directly contributes to the market's growth. The increasing number of cases necessitates the demand for diagnostic tests, treatments, and preventive measures, driving market expansion. Advanced developments in diagnostic technologies, including imaging techniques and laboratory tests, allow for more accurate and timely identification of bacterial sialadenitis. Improved diagnostic capabilities lead to quicker and more effective treatment, enhancing patient outcomes and driving market growth. Advancements in treatment modalities, such as minimally invasive techniques for abscess drainage and targeted antibiotic therapies, improve patient comfort and outcomes. Technological innovations enhance the effectiveness and safety of treatments, influencing the market positively.

However, Bacterial sialadenitis can sometimes be overlooked or misdiagnosed, particularly in its early stages or in cases with atypical presentations, leading to delayed treatment. Underdiagnosis and misdiagnosis may hinder market growth by delaying the initiation of appropriate treatment. Limited access to healthcare facilities, particularly in certain developing regions, can impede timely diagnosis and treatment of bacterial sialadenitis and potentially affect market growth.

By Type of Bacteria

  • Staphylococcus aureus
  • Streptococcus viridans
  • Pseudomonas aeruginosa
  • Escherichia coli
  • Others

By Treatment Type

  • Antibiotics
  • Surgery
  • Others

By End-User

  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Others

By Region

  • Europe
  • North America
  • Asia Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. Asia-Pacific registered the highest share in the market in 2022 due to the increasing prevalence of bacterial sialadenitis in developing countries such as China, India, and Japan. The rising geriatric population in the region is also expected to drive the market's growth. On the other hand, the European region is expected to experience significant growth in the predicted timeframe. This is due to the high occurrence of bacterial sialadenitis, along with the increasing prevalence of chronic illnesses like diabetes mellitus, HIV/AIDS, and alcoholism. Additionally, the market's growth is anticipated to be driven by the rising number of elderly people in the region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Bacterial Sialadenitis Market By Type of Bacteria, By Treatment Type, By End-User and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions—North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping-product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1. Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2. Primary Data
              1.2.1. Key Data from Primary Sources
        3. Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Bacterial Sialadenitis Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Bacterial Sialadenitis Market Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Bacterial Sialadenitis Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Bacterial Sialadenitis Market, By Type of Bacteria Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Staphylococcus aureus
        2. Streptococcus viridans
        3. Pseudomonas aeruginosa
        4. Escherichia coli
        5. Others

  • 8.  Bacterial Sialadenitis Market, By Treatment Type Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Antibiotics
        2. Surgery
        3. Others

  • 9.  Bacterial Sialadenitis Market, By End-User Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Hospitals and Clinics
        2. Ambulatory Surgical Centers
        3. Others

  • 10.  North America Bacterial Sialadenitis Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 11.  Latin America Bacterial Sialadenitis Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 12.  Europe Bacterial Sialadenitis Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 13.  Asia Pacific Bacterial Sialadenitis Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 14.  Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 15.  Market Share Analysis and Competitive Landscape
    •     1. Global Landscape - Key Players, Revenue and Presence
          2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
          3. Global Emerging Companies
          4. North America - Market Share Analysis and Key Regional Players
          5. Europe - Market Share Analysis and Key Regional Players
          6. Asia Pacific - Market Share Analysis and Key Regional Players
          7. Global Key Player - Growth Matrix

  • 16.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
    •   1. Pfizer Inc.
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Merck & Co., Inc.
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. GlaxoSmithKline plc
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Novartis AG
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Sanofi S.A.
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. Johnson & Johnson
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. Abbott Laboratories
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. Eli Lilly and Company
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. AstraZeneca plc
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. Bayer AG
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview
        11. Bristol-Myers Squibb Company
           11.1. Company Overview
           11.2. Product Portfolio
           11.3. SWOT Analysis
           11.4. Financial Overview
           11.5. Strategic Overview
        12. Roche Holding AG
           12.1. Company Overview
           12.2. Product Portfolio
           12.3. SWOT Analysis
           12.4. Financial Overview
           12.5. Strategic Overview
        13. Teva Pharmaceutical Industries Ltd.
           13.1. Company Overview
           13.2. Product Portfolio
           13.3. SWOT Analysis
           13.4. Financial Overview
           13.5. Strategic Overview
        14. Mylan N.V.
           14.1. Company Overview
           14.2. Product Portfolio
           14.3. SWOT Analysis
           14.4. Financial Overview
           14.5. Strategic Overview
        15. Allergan plc
           15.1. Company Overview
           15.2. Product Portfolio
           15.3. SWOT Analysis
           15.4. Financial Overview
           15.5. Strategic Overview

  • 17.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
            administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients